CTLA4 and cancer: We therefore analyzed the frequencies of autoreactive mature naive B cells from 4 patients with cancer before treatment, at 6 weeks — which is after 2 cycles of anti–CTLA-4 and anti–PD-1 combination therapy — and at 7 months, when only treated with anti–PD-1 for almost 5 months (Figure 2A).